Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
1597
-
Total 13F shares, excl. options
-
237M
-
Shares change
-
+491K
-
Total reported value, excl. options
-
$115B
-
Value change
-
+$570M
-
Put/Call ratio
-
0.77
-
Number of buys
-
820
-
Number of sells
-
-693
-
Price
-
$484.82
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q1 2025
1,806 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q1 2025.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 1,597 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 237M shares
of 257M outstanding shares and own 92.22% of the company stock.
Largest 10 shareholders include Capital World Investors (28.5M shares), VANGUARD GROUP INC (23.5M shares), BlackRock, Inc. (21.8M shares), Capital Research Global Investors (14.5M shares), STATE STREET CORP (11.8M shares), JPMORGAN CHASE & CO (7.76M shares), FMR LLC (7.73M shares), GEODE CAPITAL MANAGEMENT, LLC (5.76M shares), WELLINGTON MANAGEMENT GROUP LLP (5.45M shares), and JENNISON ASSOCIATES LLC (5.06M shares).
This table shows the top 1597 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.